Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingqin Ganke Granule is a Traditional Chinese Medicine (TCM) formulation developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine for the treatment of post-infectious cough (PIC). The preparation is specifically designed for patients exhibiting the TCM syndrome of "wind-heat latent in the lung," a condition characterized by persistent coughing following an acute respiratory infection. The formulation's name suggests the inclusion of *Armeniacae Semen Amarum* (Xingren) and *Scutellariae Radix* (Huangqin), which are traditionally utilized to ventilate the lung, clear heat, and suppress cough. It is currently undergoing Phase 2 clinical evaluation in a randomized, placebo-controlled dose-finding study to assess its efficacy in reducing cough severity and frequency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xingqin Ganke Granule.